ISLAMABAD:An international study found a drug that helps the blood clot has reduced life-threatening, major and critical organ bleeding in patients undergoing non-cardiac surgery without increasing major vascular complications.
A study called Peri-operative Ischemic Evaluation-3 (POISE-3) was conducted at multiple centers around the world, sponsored by Population Health Research Institute, Canada.
Shifa International Hospitals Ltd, which served as the National Coordinating Center in Pakistan under the supervision of Shifa Clinical Research Center and Principal Investigator Prof. Dr. Muhammad Amir, Consultant General Surgery and Principal Shifa College of Medicine.
This was a collaborative endeavor that involved the Aga Khan University Hospital’s research team as well.
It was noted that the concerned medicine studied, was given to individuals who were at risk of bleeding or vascular problems.
According to the study, the medicine did not increase venous thromboembolism, heart attack, non-hemorrhagic stroke, or any other severe vascular complication in the 30 days following surgery.
A senior scientist and Principal Investigator for POISE-3 at McMaster University’s Population Health Research Institute and Hamilton Health Sciences (HHS), Dr. P.J. Devereaux presented the findings at the American College of Cardiology’s 2022 conference, which was simultaneously published in The New England Journal of Medicine.
“Our research shows that the medicine can help prevent this major bleeding and the need for blood transfusions,” said Devereaux.
Professor Dr. Muhammad Amir, Consultant General Surgery and Principal Shifa College of Medicine, who is also local principal investigator and co-author of the study said that the medicine revealed a consistent reduction in the risk of bleeding based on different definitions, and it reduced the chance of receiving 1 or 2 to 4 transfusions.”
“Given that 300 million procedures are performed each year around the world,” Dr. Amir noted, the medicine has the potential for significant public health and clinical advantages.”